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patients (Hornykiewicz, 2006). Nowadays, basic research is mainly 
focused on elucidating the cause and cellular mechanisms under-
lying DA-cell degeneration. Despite these efforts, the etiology and 
pathogenesis of PD remain unclear. Current data point to it being 
more of a heterogeneous entity, arising from different causes and 
pathogenic mechanisms, and converging in a relatively uniform 
phenotype. A number of studies support the relevance of the impair-
ment of common cellular functions, such as mitochondrial metabo-
lism and protein degradation, and pathogenic mechanisms, such as 
inflammation and excitotoxicity, while others highlight the role of 
metabolic and functional aspects specific to DA-cells in the degen-
erative process. However, the relative weight of each of these factors, 
and the reason why midbrain DA-cells are particularly susceptible 
remain unknown. Our knowledge is based on data from different 
sources, including patients with familial forms of PD, whose clinical 
and pathological features in many cases differ from those in sporadic 
PD, and from animal and cellular models based on the manipulation 
of cellular functions probably involved in the pathogenesis of PD. 
The aim of this review is to summarize and discuss the current data 
in favor of and against the relevance of these factors in the sequence 
of events leading to DA-cell degeneration.
IntroductIon
The level of interest that mesostriatal dopaminergic (DA-) neurons 
have attained within the brain motor circuits in the last 30 years is 
mostly because of the relevance of this cell group in the pathophysi-
ology of Parkinson’s disease (PD). PD is a neurodegenerative disor-
der characterized by neuronal loss and the presence of intraneuronal 
inclusions known as Lewy bodies (LBs) in different brain centers 
(Braak et al., 2003), which in its sporadic form affects more than 
1% of people over the age of 60 (Nussbaum and Ellis, 2003; de Lau 
and Breteler, 2006). Besides midbrain DA-cells, this neuronal loss 
affects the locus coeruleus, dorsal nucleus of the vagus, hypothala-
mus, nucleus basalis of Meynert, olfactory bulb, and the peripheral 
and enteric systems, although they do not all display the same sus-
ceptibility to degeneration and clinical impact (Pearce et al., 1995; 
Forno, 1996). Post-mortem studies show that at the end-stage of 
the disease, the cell loss in non-dopaminergic nuclei ranges between 
30 and 50%, while in the SN it reaches 80% (Victorof et al., 1996; 
Zarow et al., 2003; Thannickal et al., 2007), with most DA-cells dying 
during the preclinical period (Greffard et al., 2006). So, the massive 
loss of SN DA-cells is considered the hallmark of PD, and responsible 
for most, if not all, motor   symptoms   characterizing   parkinsonian 
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common cellular factors and pathogenIc 
mechanIsms
mItochondrIal dysfunctIon
Mitochondria are organelles where a number of important cellular 
functions occur, including oxidative energy metabolism, calcium 
homeostasis, and control of cell death (Kroemer and Blomgren, 
2007; Celsi et al., 2009; Galluzzi et al., 2009). Furthermore, deficient 
mitochondrial metabolism may generate reactive oxygen species 
with catastrophic consequences for the cell. These facts make mito-
chondrial dysfunction an attractive candidate for playing a key role 
in neurodegeneration and aging.
The  relationship  between  mitochondrial  dysfunction  and 
DA-cell degeneration was reported for the first time by Schapira 
et al. (1990) who found reduced activity of mitochondrial complex 
I (NADH-quinone oxidoereductase) in the substantia nigra of par-
kinsonian patients. The enzymatic deficiency was later confirmed 
in the cerebral cortex (Keeney et al., 2006; Parker et al., 2008), and 
in blood platelets (Krige et al., 1992; Haas et al., 1995; Schapira, 
2008), suggesting that a number of patients can undergo a sys-
temic decrease in mitochondrial complex I activity. In addition, 
cells transfected with mitochondrial DNA from platelets of PD 
patients show complex I deficiency and other features of PD brains 
(Swerdlow et al., 1996; Borland et al., 2009).
The involvement of mitochondrial dysfunction was also sup-
ported by the finding in the early 80s of an acute and persistent 
parkinsonism in humans after intravenous injection of an illicit 
drug which contained 1-methyl-4-phenyl 1,2,3,6-tetrahydropyri-
dine (MPTP) (Langston et al., 1983). MPTP is converted by the 
monoamine oxidase enzyme of glial cells into its active metabolite 
MPP+ and taken up by DA-cells through the dopamine transporter 
(DAT). Once inside the cell, MPP+ can exert its neurotoxic effect 
by means of different mechanisms, including the inhibition of 
the mitochondrial complex I (Nicklas et al., 1985; Di Monte et al., 
1986a; Mizuno et al., 1988). Taking advantage of this effect, MPTP 
has been widely used for inducing models of PD (DA-cell degenera-
tion) in mice and monkeys (Przedborski and Jackson-Lewis, 1998; 
Blum et al., 2001).
The  structural  similarity  between  MPP+  and  the  herbicide 
paraquat raised the possibility of a relationship between exposure 
to environmental toxins, impairment of oxidative phosphoryla-
tion and PD. This idea was supported by epidemiological stud-
ies reporting a positive association between the incidence of PD 
and exposure to pesticides (Semchuk et al., 1992; Liou et al., 1997; 
Dhillon et al., 2008), although others could not confirm such a 
relationship (Firestone et al., 2005). Experimental data show that 
paraquat, subchronically administrated in mice, induces midbrain 
DA-cell loss (McCormack et al., 2002) and α-synuclein accumula-
tion (Manning-Bog et al., 2003), but its cytotoxic effect is due to 
the production of reactive oxygen species at cytosolic level, with 
potential indirect effects on mitochondria, but not to the direct 
inhibition of the mitochondrial complex I (Di Monte et al., 1986b; 
Miller, 2007). Rotenone is another pesticide widely used to induce 
an animal model of PD (Betarbet et al., 2000; Bove et al., 2005). Its 
adequacy to reproduce PD features has been a matter of contro-
versy (Cicchetti et al., 2009). Some authors argue a high variability 
in the lesion pattern, including brain regions unaffected in PD as 
well as the liver and gastrointestinal tract, suggesting that it acts as 
a systemic unspecific toxin (Hoglinger et al., 2003; Lapointe et al., 
2004). In contrast, others maintain that, by using the appropriate 
administration schedule, rotenone only produces PD specific brain 
lesions, including dopaminergic degeneration, alpha-synuclein-
positive inclusions, and impairment of the ubiquitin–proteasome 
system (UPS) (Sherer et al., 2003; Cannon et al., 2009). Because 
of its high lipophilicy, rotenone can cross all cell membranes and 
accumulates in cellular organelles. Its main cytotoxic effect comes 
from the interaction with the ND1 and PSST subunits of the mito-
chondrial complex I, resulting in the loss of its enzymatic activity 
(Schuler and Casida, 2001). Interestingly, although the complex 
I impairment is evident at the systemic level, degeneration only 
affects nigrostriatal neurons (Betarbet et al., 2000), supporting the 
idea that a systemic mitochondrial dysfunction together with the 
special susceptibility of midbrain DA-cells may be the origin of 
DA-cell degeneration in sporadic PD.
Convincing  evidence  for  the  involvement  of  mitochondrial 
dysfunction in the pathogenesis of PD also arises from the discov-
ery of mutations in genes which encode the Parkin, PINK1, DJ-1, 
α-synuclein, and LRRK2 proteins.
Mutations in the Parkin gene (PARK2) were first associated 
with PD in a Japanese family (Kitada et al., 1998). Today, they are 
recognized as the most frequent cause of juvenile-onset parkinson-
ism, although later-onset cases have also been reported (Lohmann 
et al., 2003). Parkin is a ubiquitously expressed protein, present in 
different subcellular fractions (Shimura et al., 1999), with several 
domains for protein–protein interactions and E3 ubiquitin protein 
ligase activity (Zhang et al., 2000). Parkin-associated endothelin-
receptor (Pael-R) is one of the substrates of parkin ligase activity 
which has been shown to be accumulated in the brain of patients 
with PARK2 mutations. When this receptor is overexpressed in 
cells it tends to become unfolded and insoluble, and induces cell 
death (Imai et al., 2001). Parkin has also been recognized as a mito-
chondrial protection factor. Its overexpression in cells prevents the 
mitochondrial swelling induced by ceramide (Darios et al., 2003), 
upregulates the expression of complex I subunits and reduces the 
accumulation of reactive oxygen species in mitochondria (Kuroda 
et al., 2006). While its deficiency leads to a decrease in the levels of 
complex I and IV subunits and mitochondrial respiratory capacity 
in mice (Palacino et al., 2004).
PTEN-induced putative kinase 1 (PINK1) is a serine/threonine 
kinase with autophosphorylation capacity which is transcribed in 
the nucleus, and imported to the mitochondria (Silvestri et al., 
2005). Its mutations are associated with hereditary early-onset PD, 
although heterozygous mutations have also been found in spo-
radic early-onset forms (Valente et al., 2004). PINK1 regulates the 
activity and phosphorylation of TRAP1 (TNF-receptor-associated 
protein 1), a protein which acts as a chaperone to prevent protein 
misfolding (Pridgeon et al., 2007), HtrA2/Omi, which acts as a pro-
tease involved in the degradation of misfolded proteins (Alnemri, 
2007), and Parkin. PINK1 regulates the mitochondrial localization 
of Parkin through its phosphorylation (Kim et al., 2008). Neurons 
from PINK1 knockout mice develop mitochondrial dysfunction, 
including reduced membrane potential, increased production of 
oxygen radicals and sensitivity to apoptosis (Wood-Kaczmar et al., 
2008). Furthermore, the striatum of PINK1 knockout mice shows 
an increase in the number of large mitochondria and impairment Frontiers in Neuroanatomy  www.frontiersin.org  October 2010  | Volume 4  | Article 140  |  3
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brain, but not specifically DA-cells. Furthermore, DA-cell degenera-
tion is not relevant in most neurodegenerative diseases associated 
with mutations in the nuclear genes which encode proteins that 
are targeted to mitochondria (Schon and Manfredi, 2003). Thus, 
although mitochondria impairment may be involved in the degen-
erative process in many cases of PD, other factors must contribute 
to making DA-cells particularly vulnerable in this disorder.
proteIn homeostasIs
Cells control the quantity and quality of intracellular proteins 
through the balance between the rate of their synthesis, matu-
ration and degradation (Shah and Di Napoli, 2007). Folding is 
part of this process converting newly synthesized proteins into 
functional molecules. The endoplasmic reticulum contains most 
of the machinery responsible for maintaining an appropriate pro-
tein folding through a coordinated signaling program known as 
unfolded  protein  response  (UPR)  (Hosoi  and  Ozawa,  2009). 
The response of the endoplasmic reticulum includes transla-
tional attenuation, induction of chaperones, and degradation of 
misfolded proteins. The two principal pathways of intracellular 
protein degradation are the UPS, responsible for the bulk of the 
turnover of short-lived cytosolic proteins, and the autophagy– 
lysosome pathway (ALP), involved in the degradation of long-
lived stable proteins as well as in the recycling of organelles 
(Jellinger, 2009). The capacity of this proteostasis network is 
enough to maintain protein homeostasis under normal condi-
tions and under short-term stressful circumstances. However, this 
seems to be overwhelmed by chronic stress as probably occurs 
in aging, cancer, or metabolic and neurodegenerative diseases. In 
these cases, proteins lose their normal configuration and activity, 
and become misfolded with a propensity to aggregate. The struc-
tural instability of some mutated or postranslationally modified 
proteins makes them particularly inclined to aggregate to each 
other as well as to other normal proteins. These protein aggregates 
may interfere with critical intracellular processes including UPR 
function, and induce cytotoxicity.
A number of findings indicate that these cellular functions 
are compromised in DA-cells in PD. For example, proteinaceous 
aggregations, containing ubiquitin, and α-synuclein and known as 
Lewy bodies (LBs), are abundant in the SN and other brain centers 
affected by degeneration in sporadic PD (Braak et al., 2003). The 
enzymatic activity and expression of some α-subunits of the pro-
teasome and the proteasomal activator PA700 have been found to 
be low in the SN of PD patients, while in unaffected brain regions 
they are high, suggesting that neurons in these regions, but not 
those in the SN, can activate compensatory responses against the 
proteolytic stress (McNaught et al., 2001, 2003). Even in healthy 
subjects, the levels of the proteasome activator PA28 in the SN 
pars compacta (SNc) have been reported to be lower than in other 
brain regions (McNaught et al., 2002a, 2003). In addition, a recent 
immunohistochemistry study showed that under normal condi-
tions, PA28 and PA700 expression are very low in the rat SNc, and 
that different stressful stimuli induce PA28/PA700 overexpression 
in a variety of cells but not in midbrain DA-neurons (McNaught 
et al., 2010). Therefore, it is possible that the UPS is constitutively 
weak in midbrain DA-cells, contributing to their particular vulner-
ability in sporadic PD.
of complex I and II activity (Gautier et al., 2008). So, mitochondrial 
dysfunction induced by PINK1 mutations may in part be due to 
defects in Parkin functions.
DJ-1 is a 189 amino acid/20 kDa multifunctional protein with 
antioxidant and transcription modulatory activity (Takahashi et al., 
2001; Taira et al., 2004). Under normal conditions, DJ-1 prefer-
entially localizes in the cytosol, but under conditions of oxidative 
stress it translocates to the mitochondria and nucleus (Zhang et al., 
2005). This redistribution ability has been related to its neuro-
protective capacity (Canet-Aviles et al., 2004; Ashley et al., 2009). 
Mutations in its encoding gene (PARK7) are a rare cause of reces-
sively inherited PD (Bonifati et al., 2003). DJ-1 deficient mice show 
motor abnormalities and changes in DA handing, but not sponta-
neous DA-cell degeneration (Goldberg et al., 2005). However, they 
become more susceptible to MPTP than their wild-type congeners 
(Kim et al., 2005).
Alpha-synuclein is a presynaptic protein whose relevance in PD 
comes from the fact that it is present in LBs, and because muta-
tions and triplications of its gene locus (PARK1) are a cause of 
autosomal dominant PD (Polymeropoulos et al., 1997; Singleton 
et al., 2003). The mechanism by which α-synuclein exerts its tox-
icity has been related to the tendency of the mutated and over-
expressed protein to aggregate in form of fibrils (Conway et al., 
2000; Fredenburg et al., 2007). Oligomeric intermediates of the 
α-synuclein fibrillation pathway, called protofibrils, can form annu-
lar pores in cell membranes, including those of mitochondria, lead-
ing to their permeabilization. This phenomenon may be enhanced 
in DA-cells because cytosolic DA interacts with α-synuclein slowing 
the conversion of protofibrils to fibrils (Conway et al., 2000; Rochet 
et al., 2004). Overexpression of mutant and wild-type α-synuclein 
can induce damage at different cell levels, including proteasome, 
endoplasmic  reticulum,  and  mitochondria  (Hsu  et  al.,  2000). 
Mitochondrial impairment includes oxidation of mitochondria-
associated proteins (Poon et al., 2005), mitochondrial DNA dam-
age and reduced complex IV activity (Martin et al., 2006). In this 
respect, higher α-synuclein levels have been found in mitochondria 
from substantia nigra of PD patients than in those from healthy 
individuals (Devi et al., 2008).
Leucine-rich repeat kinase 2 (LRRK2) is a widely distributed 
protein with a multidomain structure which includes a serine/
threonine kinase domain (Giasson et al., 2006). Mutations in the 
gene encoding LRRK2 (PARK8) are a common cause of autosomal 
dominant PD, and are also present in about 1% of patients with 
sporadic PD (Paisan-Ruiz et al., 2004; Di Fonzo et al., 2005). The 
toxicity of several of these mutations appears to be associated with 
an increase in its kinase activity (Gloeckner et al., 2006). Although 
the involvement of mitochondria in the pathogenesis of LRRK2 
mutant-associated PD remains unclear, the facts that LRRK2 par-
tially colocalizes with mitochondrial markers (Biskup et al., 2006), 
and that overexpression of mutant LRRK2 proteins induces Apaf1 
dependent apoptosis (Iaccarino et al., 2007), suggest that LRRK2 
mutations can compromise mitochondrial function.
In sum, a large body of evidence supports the idea that mito-
chondrial dysfunction plays a key role in the pathogenesis of DA-cell 
degeneration. However, this idea is challenged by certain facts. For 
example, diseases associated with mitochondrial DNA mutations 
are typically multisystemic, involving heart, skeletal muscle, and Frontiers in Neuroanatomy  www.frontiersin.org  October 2010  | Volume 4  | Article 140  |  4
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autophagy (CMA) (Cuervo et al., 2004). In CMA, α-synuclein cou-
ples to the chaperone Hsc70 forming a protein–molecular chaperone 
complex that binds to the lysosomal membrane (Mak et al., 2010). 
The A30P and A53T α-synuclein mutants, which are associated 
with familial PD, remain firmly attached to the chaperone, block-
ing their lysosomal translocation and degradation, and the binding 
of other CMA protein substrates (Cuervo et al., 2004; Pan et al., 
2008). In addition, missense mutations of the gene encoding lyso-
somal ATPase 13A2 (PARK9), which are associated with an atypical 
form of juvenile-onset PD, lead to deficient autophagy activity with 
α-synuclein aggregation (Ramirez et al., 2006).
In spite of the unequivocal evidence for the impairment of pro-
teostasis in the pathogenesis of DA-cell degeneration, it is still not 
clear whether degeneration starts with this phenomenon, whether 
the proteolytic stress does or does not play a determinant role in 
the relative specificity of DA-cell loss in PD, and whether LB-like 
proteinaceous inclusions are toxic entities promoting neuron death 
or whether they represent protective mechanisms by which neu-
rons sequester unwanted proteins (Harrower et al., 2005). Based 
on the regional distribution of LBs, Braak et al. (2003) proposed 
a neuropathological staging scheme according to which PD starts 
in non-dopaminergic structures of the medulla oblongata and 
progresses rostrally, affecting nigral DA-cells later on in the course 
of the disease. However, this idea contrasts with quantitative studies 
reporting that most SN cell loss and striatal denervation occurs dur-
ing the 5–10 year preclinical period (Gibb and Lees, 1988; Greffard 
et al., 2006), suggesting that cell loss and α-synuclein deposition 
are not parallel processes (Burke et al., 2008). It should also be 
noted that LBs and α-synuclein immunoreactive inclusions are 
present in different brain regions in different neurodegenerative 
diseases encompassed by the term LB disorders, including PD with 
dementia and dementia with LBs (Lippa et al., 2007), and in normal 
aging (Hindle, 2010); that the density of LBs in neurodegenerative 
diseases does not correlate with the intensity of cell degeneration, 
and that LBs are virtually absent in juvenile-onset PD associated 
with Parkin mutations (Olanow and McNaught, 2006).
neuroInflammatIon
The participation of inflammatory reaction in the degeneration of 
midbrain DA-cells was suggested for the first time by the report of 
an increased number of microglial cells immunoreactive for the 
major histocompatibility complex (MHC) antigen II in the SN of 
PD patients (McGeer et al., 1988). The presence of activated micro-
glia was thereafter confirmed using other markers of microglial 
activation (Mogi et al., 1994a; Banati et al., 1998; Imamura et al., 
2003). The fact that DA-cells express the receptors for some of the 
cytokines found in the SN of PD patients, such as the tumor necrosis 
factor (TNF) α, interleukin (IL)-1β and interferon γ (Boka et al., 
1994), and that the expression of some of these, e.g., TNFα receptor 
1, increases in PD (Mogi et al., 2000), indicates that DA-cells may 
be sensitive to the direct effect of cytokines. However, cytokines 
can also affect DA-cells by inducing enzymes such as nitric oxide 
synthase, cyclo-oxygenase 2, and NADPH-oxidase which produce 
toxic reactive species (Hunot et al., 1996; Knott et al., 2000).
Interestingly, an analysis of cerebrospinal fluid in PD patients 
showed  an  increase  in  TNFα,  IL-1β,  and  IL-6  concentration 
(Mogi et al., 1994b; Blum-Degen et al., 1995), and an analysis of 
The relevance of proteolytic stress is also supported by data aris-
ing from familial PD. As mentioned above, although the mechanism 
by which Parkin mutations induce degeneration is not well known, 
it has been mainly related to a defect in its ubiquitin ligase activity. 
Parkin interacts with the 26S proteosome through its ubiquitin 
ligase domain facilitating the recognition of ubiquitinated sub-
strates by the proteasomal activator PA700 (Pickart, 2004). Parkin 
acts in conjunction with other enzymes to ubiquitinate a variety 
of substrates, such as Pael-R, which have been found to be accu-
mulated and non-ubiquinated in LBs (Murakami et al., 2004). In 
addition, Parkin prevents cell death induced by overexpression of 
Pael-R (Imai et al., 2001). Therefore, Parkin mutations could impair 
ubiquitination and degradation of substrate proteins which might 
be aggregated and cause cytotoxicity.
Ubiquitin C-terminal hydrolase L1 (UCH-L1) is a 230 amino 
acid/26 kDa protein only expressed in neurons, which acts as a 
deubiquinating enzyme removing ubiquitin from protein adducts 
before their entry in the proteosome (Leroy et al., 1998). A missense 
mutation in the UCH-L1 gene (PARK5) has been found in two 
German siblings with PD, and is considered today to be a rare cause 
of familiar PD (Olanow and McNaught, 2006). It has been reported 
that the in vitro deubiquinating activity of mutated UCH-L1 form 
is low (Nishikawa et al., 2003), and that inhibition of the ubiquitin 
hydrolase activity leads to the formation of LB-like inclusions and 
DA-cell degeneration in cell cultures (McNaught et al., 2002b). So, 
it is possible that, in these patients, deubiquitination failure blocks 
the proteasomal processing of proteins, leads to the formation of 
aggregates and interferes with the supply of ubiquitin monomers 
to additional unwanted proteins (Olanow and McNaught, 2006).
The protective role of DJ-1 has been mostly associated to its 
ability to translocate to the mitochondria and nucleus where it can 
exert antioxidant and transcriptional modulatory actions (Zhang 
et al., 2005). However, its molecular structure and in vitro proper-
ties indicate that it can also work as a molecular chaperone and 
protease (Abou-Sleiman et al., 2003; Lee et al., 2003). In addition, 
such proteolytic activity is lost when it is mutated (Olzmann et al., 
2004; Shendelman et al., 2004). So, mutations in DJ-1 can compro-
mise UPS function and promote protein aggregation.
Under  physiological  conditions,  α-synuclein  is  monomeric 
and unfolded, and preferentially degraded by the proteasome in 
an ubiquitin-independent manner (Bennett et al., 1999). But in 
high concentration or as a mutated form, it resists proteasomal 
degradation (Stefanis et al., 2001; Tanaka et al., 2001), becomes 
misfolded and oligomeric, and tends to self-aggregate and aggregate 
to other proteins (Bennett, 2005). As mentioned above, the toxicity 
of α-synuclein has been related to the ability of α-synuclein inter-
mediate aggregates to form ring-like pores in cellular membranes, 
increasing their permeability (Lashuel et al., 2002). In vitro studies 
reveal that α-synuclein aggregates can also bind to the proteasomal 
protein S6’, a subunit of the 19S cap of the 26S proteasome, resulting 
in the inhibition of its function (Snyder et al., 2003).
On the other hand, similar to other protein complexes and mem-
brane proteins too large in size to pass through the proteasome barrel, 
α-synuclein oligomers and aggregates can also be cleared by the ALP 
(Pan et al., 2008). The principal pathways for α-synuclein clearance 
through lysosomes are the macroautophagy, which is also involved 
in the recycling of damaged organelles, and the chaperone-mediated Frontiers in Neuroanatomy  www.frontiersin.org  October 2010  | Volume 4  | Article 140  |  5
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1997). Extracellular glutamate comes from two different sources, 
the neuronal Ca2+-dependent pool, and the glial Ca2+-independent 
pool. Under basal conditions, the glial pool provides 60% of extra-
cellular glutamate, although at present its functional relevance is 
controversial. After K+-induced depolarization, the neuronal pool 
augments from 30% to 60% of the total extracellular glutamate 
(Xue et al., 1996; Baker et al., 2002; Cavelier and Attwell, 2005). 
Current data show that the glutamatergic input to the SN comes 
from the pedunculopontine tegmental nucleus (PPN), and par-
ticularly from the subthalamic nucleus (STN) (Charara et al., 1996; 
Iribe et al., 1999; Forster and Blaha, 2003). Curiously, hodological 
and electron microscopic studies indicate that the bulk of sub-
thalamic afferents to the SN reach the pars reticulata and form 
asymmetrical synapses with TH-negative (presumably GABAergic) 
dendrites, with those making contact with TH-positive being more 
than 10% (Kita and Kitai, 1987). So, depending on the target cell 
and the receptor type, glutamate can directly excite DA-cells, indi-
rectly inhibit them by exciting GABAergic neurons, and directly 
inhibit or excite them by activating metabotropic receptors on 
DA-cells (Lee and Tepper, 2009).
Glutamate signaling may be affected by alterations in its home-
ostasis, which leads to an increase in the extracellular concentra-
tion, or by alterations in the energy metabolism of its target cells, 
which lead to a decrease in the activation threshold for their recep-
tors, particularly those of the NMDA type (Novelli et al., 1988). 
Experimental data indicate that glutamate might contribute to 
DA-cell degeneration by means of both mechanisms. In a model 
of PD in mice, the loss of striatal DA-terminals is accompanied by 
an increase in the size and number of astrocytes, but the density 
of transporters per astrocyte is low, suggesting that the astrocyte 
function is compromised (Dervan et al., 2004). On the other hand, 
NMDA antagonists reduce the loss of DA-neurons due to the inhi-
bition of the cellular metabolism in midbrain cell culture (Zeevalk 
et al., 1998), and the loss of DA-cells induced by MPP+ and MPTP 
in rodents and in non-human primates (Turski and Lachowicz, 
1991). STN activity has been found to be enhanced in both the 
experimental models of PD (Bergman et al., 1994) and in the PD 
patients (Benazzouz et al., 2002), and its modulation results in an 
improvement of motor symptoms (Limousin et al., 1998; Garcia 
et al., 2005). Hyperactivity of STN has even been detected before the 
appearance of clinical signs in MPTP-treated monkeys, suggesting 
that it may be a compensatory mechanism for the maintenance 
of striatal dopaminergic homeostasis (Bezard et al., 1999a), but it 
could also contribute to the progression of DA-cell loss from the 
first stages of the disease.
agIng
The relationship between aging and DA-cell degeneration is based on 
several facts. PD in its sporadic form is an age-related degenerative 
disorder, with a mean onset age of 55, and the incidence increases 
from 20/100.000 to 120/100.000 at age 70 (Dauer and Przedborski, 
2003). Lewy bodies, the pathological hallmarks of PD (Braak et al., 
2003), are also present in normal aged brains (Saito et al., 2004; 
Hindle, 2010). Oxidative stress is currently considered to play a cen-
tral role in both aging (Harman, 1956; Squier, 2001) and PD (Dauer 
and Przedborski, 2003; Jenner, 2003). Mitochondrial DNA dele-
tions occurring during normal aging, probably as a consequence 
peripheral blood showed an increase in activated CD4(+) CD25(+) 
lymphocytes (Bas et al., 2001). Furthermore, the population of 
circulating CD3+ CD4 bright+ CD8 dull+ lymphocytes is signifi-
cantly greater in PD patients than in age-matched control sub-
jects (Hisanaga et al., 2001). Since the count of these lymphocytes 
usually increases after a viral infection, the authors proposed that 
postinfectious immune abnormalities could be associated with the 
pathogenesis of PD.
Animal and cellular models of PD have reproduced most cellular 
and molecular inflammatory events observed in the brain of PD 
patients, but have also provided additional insight for understand-
ing the role of inflammation in DA-cell degeneration. For example, 
microglial activation has been found in the SN of mice and monkeys 
after peripheral injection of MPTP (Liberatore et al., 1999; Hurley 
et al., 2003; McGeer et al., 2003). The addition of α-synuclein or 
neuromelanin, two products released by degenerating DA-cells, to 
microglial cultures induces activation of proinflammatory path-
ways, and the injection of α-synuclein protofibrils in the rat SN 
induces microglial activation and loss of adjacent neurons (Wilms 
et al., 2003, 2009). Furthermore, the administration of steroidal 
and non-steroidal anti-inflammatory drugs reduce the toxicity of 
6-OHDA and MPTP in rodents (Kurkowska-Jastrzebska et al., 2002; 
Di Matteo et al., 2006; Hirsch and Hunot, 2009). Taken together, 
these findings suggest that damaged DA-cells might upregulate 
and/or release products which activate microglial cells, and these 
lead to a local neuroinflammatory reaction which helps to perpetu-
ate degeneration. Interestingly, recent in vivo and in vitro studies 
show that DA-degeneration induces an increase in the activity of 
angiotensin converting enzyme and angiotensin II (AII) levels, that 
the addition of AII to midbrain cell cultures increases 6-OHDA 
toxicity, and that angiotensin type-1 receptor antagonists inhibit 
both DA-cell degeneration and NADPH-oxidase and early micro-
glial activation (Muñoz et al., 2006; Rodriguez-Pallares et al., 2008; 
Joglar et al., 2009). So, the brain angiotensin system may play a key 
role in the inflammatory process in PD. The fact that inflamma-
tory changes are also present in other neurodegenerative disorders, 
such as Alzheimer’s disease, Huntington’s disease and amyotrophic 
lateral sclerosis (McGeer and McGeer, 2004), suggests a common 
phenomenon in the progression of neuronal degeneration.
glutamate excItotoxIcIty
Glutamate is the major excitatory neurotransmitter in the mam-
malian brain, and is also a potent neurotoxin when it reaches high 
extracellular concentrations. The levels of extracellular glutamate 
are regulated by neuronal and glial transporters, and by its metabo-
lism and recycling via glutamine synthetase in astrocytes, which 
prevent the extracellular glutamate concentration from rising to 
neurotoxic values (Plaitakis and Shashidharan, 2000; Dervan et al., 
2004). Glutamatergic actions are exerted through two families of 
glutamate receptors, ionotropic and metabotropic. According to 
their agonist selectivity, ionotropic receptors have been classified 
into:  N-methyl-d-aspartate  (NMDA),  α-amino-3-hydroxyl-5-
methyl-4-isoxazole-propionate  (AMPA),  and  kainic  acid  (KA) 
receptors  (Burnashev  et  al.,  1992;  Hollmann  and  Heinemann, 
1994; Geiger et al., 1995). Metabotropic receptors are coupled by 
G-proteins to different secondary messenger systems, and have also 
been classified into different groups (Groups I–III; Conn and Pin, Frontiers in Neuroanatomy  www.frontiersin.org  October 2010  | Volume 4  | Article 140  |  6
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should be linked to physiological, neurochemical, and/or meta-
bolic aspects which are specific to DA-cells and also differ from 
one DA-subpopulation to another, making some of them more 
vulnerable or resistant.
physIologIcal profIle of da-neurons
A characteristic of midbrain DA-cells is that, unlike most neurons 
in the brain, they display two electrophysiological patterns. One 
phasic pattern in the form of bursts of action potentials with a 
mean frequency of 20 Hz and triggered by excitatory inputs from 
different sources (Schultz, 2002; Omelchenko and Sesack, 2005), 
and the other tonic pattern, with a mean frequency of 2–4 Hz and 
which is generated in absence of afferents (Sulzer and Schmitz, 
2007). This intrinsic pacemaking activity is believed to be impor-
tant in maintaining basal DA levels in the striatum, and may be 
detected from the first postnatal days in mice. During the first 
weeks, this is driven by sodium and hyperpolarization-activated 
and cyclic nucleotide-gated cation (Na+/HCN) channels. Thereafter, 
the expression of L-type Ca2+ channels increases in SN DA-cells, 
and the pacemaking is driven by Ca2+ currents. Adult VTA DA-cells 
also have L-type Ca2+ channels, but as opposed to SN DA-cells, their 
pacemaking continues to be driven by sodium channels. The L-type 
Ca2+ channels used by SN DA-cells have a Cav 1.3 pore-forming 
subunit which allows them to open at a relatively hyperpolarized 
potential (Striessnig et al., 2006; Chan et al., 2007). While in most 
cells, Ca2+ channel opening is a rare and brief event, the sustained 
used of Cav 1.3 Ca2+ channels by SN DA-cells results in a large 
Ca2+ influx which requires a high metabolic cost to be handled. 
Cytosolic Ca2+ should be pumped back across the plasma mem-
brane against a concentration gradient or rapidly sequestered. The 
two organelles most directly involved in Ca2+ handling are ER and 
mitochondrion. Cytosolic Ca2+ is moved into ER by high-affinity 
ATP-dependent transporters. Thereafter, it is released to the cytosol 
to be used in modulatory functions or pumped to the extracellular 
space (Berridge, 2002; Choi et al., 2006). Ca2+ released from the ER 
can also enter mitochondria through apposition points between 
both organelles (Rizzuto and Pozzan, 2006). This ER-mitochondrial 
system contributes to Ca2+ buffering but also to ATP production 
(McCormack et al., 1990). However, it may be overburdened by the 
sustained use of Cav1.3 Ca2+ channels. Both depletion and increase 
in intraluminal ER Ca2+ concentration induce ER stress and com-
promise  proteostasis  (LaFerla,  2002;  Paschen  and  Mengesdorf, 
2005). Furthermore, the high demand of ATP needed to move Ca2 
out of the cell increases the electron transport chain activity leading 
to the production of reactive oxygen species (Sulzer and Schmitz, 
2007; Chan et al., 2009). The relevance of the Ca2+-dependence of 
pacemaking activity in the vulnerability of SN DA-cells is based 
on the finding that blockade of Cav1.3 Ca2+ channels in adult SN 
DA-cells induces a reversion of the pacemaking pattern to that of 
adult VTA and juvenile SN DA-cells, also protecting them against 
rotenone and MPTP (Chan et al., 2007). Reinforcing the role Ca2+ 
homeostasis in the differential vulnerability of midbrain DA-cells, 
DA-cells in the dorsomedial region of SN and VTA express cal-
bindin-D28k (Gerfen et al., 1987; McRitchie and Halliday, 1995; 
Liang et al., 1996; McRitchie et al., 1996). The ability of this pro-
tein to buffer intracellular Ca2+, together with its localization in 
DA-cell subpopulations resistant to degeneration, have suggested 
of oxidative stress, are particularly abundant in midbrain DA-cells 
(Bender et al., 2006; Kraytsberg et al., 2006). In addition, morpho-
logical studies in monkeys (Pakkenberg et al., 1995; Gerhardt et al., 
2002) and humans (McGeer et al., 1977; Fearnley and Lees, 1991; 
Pakkenberg et al., 1995; Cabello et al., 2002; Gerhardt et al., 2002) 
have reported a decrease in the number of midbrain DA-cells with 
age, suggesting that midbrain DA-neurons undergo a low intensity 
degenerative process during normal aging. Based on these findings, 
it has been proposed that everyone should get PD if they live long 
enough (Chan et al., 2007; Surmeier, 2007). However, this idea is 
challenged by other studies performed on monkeys (Irwin et al., 
1994; McCormack et al., 2004; Collier et al., 2007) and humans 
(Kubis et al., 2000) according to which the number of midbrain 
DA-cells does not change during normal aging, suggesting that the 
age-related loss of striatal DA levels (Kish et al., 1992; Haycock et al., 
2003) is due to a progressive chemical and functional decline rather 
than to degeneration. Furthermore, biochemical studies performed 
on humans show that the regional pattern of striatal DA loss during 
normal aging substantially differs from that typically observed in 
PD (Kish et al., 1992). Consistent with these data, we have recently 
observed that the loss of DA in aged rats is higher in the ventral 
striatum than in the dorsal striatum (Cruz-Muros et al., 2007). In 
addition, two different age-related processes were detected. One is 
characterized by DOPA decarboxylase decrease involving both the 
nigrostriatal and the mesolimbic compartments, and is responsible 
for the moderate DA decrease in the dorsal striatum. The other 
process is characterized by axonal degeneration and aggregation 
of α-synuclein in their original somata, restricted to mesolimbic 
regions and responsible for the decline of tyrosine hydroxylase 
activity and the greater decrease in DA levels in this compartment. 
Therefore, although both the nigrostriatal and the mesolimbic sys-
tems are vulnerable to aging, in contrast to what occurs in PD, 
the mesolimbic system seems to be more vulnerable to normal 
aging than the nigrostriatal system. Furthermore, although several 
age-related aspects, such as oxidative stress or impairment of the 
energy metabolism, make aging the most important risk factor 
for PD, anatomical and biochemical features of normal aging in 
the mesostriatal system seem to be more probably related to age-
associated behavioral and mood disturbances than to parkinsonian 
motor signs.
specIfIc dopamInergIc factors
The aforementioned studies indicate that intrinsic (mitochondrial 
dysfunction and proteostasis impairment), extrinsic (neuroinflam-
mation and excitotoxicity) and age-related factors participate in 
the degenerative process of DA-cells in PD. However, a question 
of critical importance remains to be solved: why are midbrain 
DA-neurons, and especially some of these neurons, particularly 
vulnerable to degeneration? It is known that in PD, DA-cells in the 
SN are more vulnerable than those in the VTA, and that within the 
SN, neurons lying in its ventrolateral and caudal region (SNcv) are 
more vulnerable than those in the rostromedial and dorsal region 
(SNrm) (Hassler, 1938; German et al., 1989; Damier et al., 1999). 
However, there is no evidence for substantial differences in the 
ER, mitochondria or other structural organelles between DA-cells 
and non-DA cells, or between midbrain DA-cells that show dif-
ferent susceptibility to degeneration. So, differential vulnerability Frontiers in Neuroanatomy  www.frontiersin.org  October 2010  | Volume 4  | Article 140  |  7
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MPP+ (D’Amato et al., 1986) and paraquat (Lindquist et al., 1988), 
reducing their neurotoxicity, and accumulate dopaminergic drugs, 
regulating their intracellular concentration (Salazar et al., 1978). 
Neuromelanin also has the capability to sequester redox-active ions, 
including iron, thereby reducing the formation of free hydroxyl 
radicals (Enochs et al., 1994; Zecca et al., 2003). However, under 
oxidative conditions, neuromelanin can interact with hydrogen per-
oxide, becoming a source of free radicals and releasing toxic metals 
which accelerate cell death (Swartz et al., 1992; Shima et al., 1997). 
In addition, as mentioned above (Wilms et al., 2003), neuromelanin 
released from degenerated DA-cells can induce microglial activa-
tion, also perpetuating the degenerative process.
It should be also noted that the cytosolic levels of DA are closely 
related to two transport processes: DA uptake from the extracel-
lular space, and once inside the cell, DA packing into small synaptic 
vesicles. DA uptake is performed by the DAT, a 12-transmembrane 
domain glycoprotein with three N-glycosylation sites in the sec-
ond extracellular loop (Horn, 1990; Giros and Caron, 1993; Uhl 
et al., 1994). DA vesicular storage is performed by the vesicular 
monoamine transporter type 2 (VMAT2), also present in other 
monoaminergic cells (Miller et al., 1999). DAT may contribute to 
the vulnerability of DA-cells serving as an entrance for DA and its 
metabolites, while VMAT2 may serve as a neuroprotective factor 
by sequestering DA into vesicles, and preventing interaction with 
their catabolic enzymes. So, the functional balance between both 
transporters may affect the differential vulnerability between dif-
ferent midbrain DA-cell subpopulations. This idea is supported 
by the fact that VMAT2 deficient mice are more susceptible to 
MPTP than their homologous wild-type (Takahashi et al., 1997). 
Furthermore, they display spontaneous and progressive DA-cell 
degeneration (Caudle et al., 2007), and non-motor parkinsonian 
symptoms (Taylor et al., 2009), suggesting that VMAT2 may also 
be involved in the degeneration of other monoaminergic cells in 
PD. Studies carried out in our laboratory show that during normal 
aging, in parallel with the decline in vesicular DA uptake, VMAT2 is 
deglycosylated and moved from the vesicle membrane to the soluble 
compartment (Cruz-Muros et al., 2008), probably contributing to 
the increase of the vulnerability of DA-cells with age.
On the other hand, the damaging role of DAT is supported by 
the fact that its expression and functional integrity are required 
for making DA-cells susceptible to DA analog neurotoxins (Kopin, 
1992; Gainetdinov et al., 1997; Bezard et al., 1999b), and by the 
report of an anatomical correlation between the distribution of 
DA-neurons expressing high DAT mRNA levels and those showing 
high vulnerability to degeneration in PD and animal models of PD 
(Cerruti et al., 1993; Hurd et al., 1994; Uhl et al., 1994). However, 
this correlation does not apply in some DA-cell groups. DA-cells 
in the parabrachialis pigmentosus region of the A10 cell group, 
which contain higher levels of DATmRNA than those in the dor-
sal tier of SN in monkeys (Haber et al., 1995) and rats (Shimada 
et al., 1992) are also more resistant to MPTP (Varastet et al., 1994) 
and 6-OHDA (Rodriguez et al., 2001) respectively. In addition, a 
comparative analysis of DAT and VMAT2 mRNA expressions in 
the ventral midbrain of rats revealed no differences between both 
mRNA expression patterns, with the highest levels in the SNrm, 
followed by the SNcv, and the lowest ones in VTA (Gonzalez-
Hernandez et al., 2004). So, the involvement of DA transporters 
that calbindin-D28k confers neuroprotection (Gerfen et al., 1985; 
Yamada et al., 1990; German et al., 1992). However, some findings 
contrast with this hypothesis. For example, no differences have been 
observed between the neurotoxic effect of MPTP in midbrain-DA 
cells of calbindin-D28k-deficient mice and their wild-type litterma-
tes (Airaksinen et al., 1997). Furthermore, DA-cells in the lateral 
region of the SN which express calbindin-D28k are more sensitive 
to the neurotoxic effect of 6-OHDA than other SN DA-cells which 
do not express calbindin-D28k (Rodriguez et al., 2001).
metabolIc phenotype of da-neurons
Another peculiarity of DA-cells implicated in their vulnerability 
concerns DA itself. Under normal conditions, most DA acting as a 
neurotransmitter is contained inside synaptic vesicles of DA-cells 
(Jonsson, 1971). When DA concentration increases in the cytosol, 
DA is rapidly metabolized via monoamino oxidase or by autooxi-
dation. Both enzymatic and non-enzymatic catabolisms of DA 
are important sources of reactive oxygen species which have been 
implicated in DA-cell degeneration. Through its enzymatic metabo-
lism, DA is converted into 3,4-dihydroxyphenylacetaldehyde and 
3,4-dihydroxyphenylacetic acid, also generating hydrogen perox-
ide. This may be neutralized by antioxidant enzymes, or, in the 
presence of iron, generate high toxic hydroxyl radicals. Through 
autooxidation, DA is converted into reactive quinones and super-
oxide anion. This can be converted into hydrogen peroxide by 
superoxide dismutase, or react with nitric oxide to generate the 
highly toxic radical peroxynitrite (Barzilai et al., 2001). Reactive 
quinones may be oxidized to cyclized aminochromes, which are 
thereafter polymerized to form neuromelanin, or interact with 
cysteine residues of different molecules inhibiting their activity 
(Miyazaki and Asanuma, 2009). On the basis of this interaction, 
the formation of quinones by DA oxidation has gained interest in 
the pathogenesis of PD. There are studies supporting the notion 
that DA-quinone, or some of its metabolic products, can inhibit 
the ubiquitin ligase activity of parkin (LaVoie et al., 2005), the 
permeability of mitochondrial pores (Berman and Hasting, 1999) 
and the proteasomal function (Zafar et al., 2006), as well as induce 
microglial activation (Kuhn et al., 2006).
Neuromelanin is another product from the DA metabolism that 
has been implicated in the pathogenesis of PD. Neuromelanin is a 
complex polymeric molecule which probably arises from both the 
enzymatic (Hasting, 1995; Sanchez-Ferrer et al., 1995) and non-
enzymatic (Fornsted et al., 1986; Sulzer et al., 2000) metabolism of 
catecholamines, and is particularly abundant in DA-cells in the SN 
and noradrenergic cells in the locus coeruleus of humans, being 
responsible of their dark color (Fasano et al., 2006). Neuromelanin 
was first proposed as playing a role in PD on the basis of mor-
phological studies reporting a correlation between neuromelanin 
concentration and DA-cell degeneration (Mann and Yates, 1983; 
Hirsch et al., 1988). However, this idea was challenged by the report 
that DA-cells in the dorsal tier of the SN contain higher levels of 
neuromelanin than those in the ventral tier which are more vul-
nerable to degeneration (Gibb, 1992). Experimental studies per-
formed during the last two decades indicate that neuromelanin 
may play a dual role, protecting from or contributing to DA-cell 
degeneration, depending on the environment (Ben-Shachar et al., 
1991; Sulzer et al., 2000). On the one hand, neuromelanin can bind Frontiers in Neuroanatomy  www.frontiersin.org  October 2010  | Volume 4  | Article 140  |  8
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all cells is the main factor responsible for degeneration of particular 
neuronal groups. Ca2+-dependent pacemaking and DA handling 
are two oxidative stress generating activities specific to midbrain 
DA-cells. The reliance on Cav1.3 Ca2+ channels to drive pacemaking 
and the pattern of DAT maturation and DA uptake also explain 
the differential susceptibility between nigrostriatal and mesolimbic 
neurons. Morphological and molecular studies performed in the 
last 20 years, with the aid of laser capture microdissection and more 
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